19 June 2013
Keywords: synta, gets, 80m, upfront, payment, gsk, usa
Article | 10 December 2007
The USA's Synta Pharmaceuticals has received an upfront non-refundable cash payment of $80.0 million from UK drug major
GlaxoSmithKline following expiration ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 December 2007
18 June 2013
© 2013 thepharmaletter.com